BR9607169A - Uso de meletonina e formulação farmacêutica para uso no tratamento de um viciado em drogas múltiplas - Google Patents

Uso de meletonina e formulação farmacêutica para uso no tratamento de um viciado em drogas múltiplas

Info

Publication number
BR9607169A
BR9607169A BR9607169A BR9607169A BR9607169A BR 9607169 A BR9607169 A BR 9607169A BR 9607169 A BR9607169 A BR 9607169A BR 9607169 A BR9607169 A BR 9607169A BR 9607169 A BR9607169 A BR 9607169A
Authority
BR
Brazil
Prior art keywords
meletonin
treatment
pharmaceutical formulation
multiple drug
drug addict
Prior art date
Application number
BR9607169A
Other languages
English (en)
Portuguese (pt)
Inventor
Nava Zisapel
Original Assignee
Neurim Pharma 1991
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/381,535 external-priority patent/US6469044B1/en
Application filed by Neurim Pharma 1991 filed Critical Neurim Pharma 1991
Publication of BR9607169A publication Critical patent/BR9607169A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR9607169A 1995-02-01 1996-01-29 Uso de meletonina e formulação farmacêutica para uso no tratamento de um viciado em drogas múltiplas BR9607169A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/381,535 US6469044B1 (en) 1995-02-01 1995-02-01 Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
EP95303853A EP0724878B1 (en) 1995-02-01 1995-06-06 Use of melatonin for treating patients suffering from drug dependencies
PCT/IB1996/000082 WO1996023496A1 (en) 1995-02-01 1996-01-29 Use of melatonin for treating patients suffering from drug addiction

Publications (1)

Publication Number Publication Date
BR9607169A true BR9607169A (pt) 1997-11-11

Family

ID=26140195

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9607169A BR9607169A (pt) 1995-02-01 1996-01-29 Uso de meletonina e formulação farmacêutica para uso no tratamento de um viciado em drogas múltiplas

Country Status (22)

Country Link
JP (1) JP4516159B2 (cs)
CN (1) CN1083263C (cs)
AT (1) AT408188B (cs)
AU (1) AU695366B2 (cs)
BG (1) BG62876B1 (cs)
BR (1) BR9607169A (cs)
CZ (1) CZ291349B6 (cs)
DK (1) DK176081B1 (cs)
EE (1) EE03384B1 (cs)
FI (1) FI119586B (cs)
IS (1) IS1980B (cs)
LU (1) LU90118B1 (cs)
LV (1) LV11940B (cs)
MD (1) MD1716C2 (cs)
NO (1) NO312814B1 (cs)
NZ (1) NZ298878A (cs)
PL (1) PL183148B1 (cs)
SI (1) SI9620022A (cs)
SK (1) SK284521B6 (cs)
TR (1) TR199700723T1 (cs)
TW (1) TW483757B (cs)
WO (1) WO1996023496A1 (cs)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001049286A1 (en) 2000-01-05 2001-07-12 Neurim Pharmaceuticals (1991) Ltd. Method and formulation for treating resistance to antihypertensives and related conditions
IL149377A (en) * 2002-04-28 2012-10-31 Neurim Pharma 1991 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
US9119846B2 (en) 2003-04-29 2015-09-01 Neurim Pharmaceuticals (1991) Ltd. Method and composition for enhancing cognition in alzheimer's patients
IL155666A (en) 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
PT2806863T (pt) 2012-01-26 2017-11-09 Vanda Pharmaceuticals Inc Tratamento de perturbações do ritmo circadiano
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
EP3767297A1 (en) 2012-12-18 2021-01-20 Vanda Pharmaceuticals Inc. Method of determining tau and thereby determining whether a patient has a free-running circadian rhythm
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
HRP20250166T1 (hr) * 2016-10-31 2025-05-09 Neurim Pharmaceuticals Ltd. Mini tablete melatonina i način proizvodnje istih

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122007000073I1 (de) * 1991-05-09 2008-01-31 Neurim Pharma 1991 Melatonin enthaltene Arzneimittel
IT1251544B (it) * 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico

Also Published As

Publication number Publication date
TR199700723T1 (xx) 1998-02-21
LU90118B1 (fr) 1997-11-13
AU4457496A (en) 1996-08-21
NO973531D0 (no) 1997-07-31
DK89697A (da) 1997-07-30
TW483757B (en) 2002-04-21
CN1172431A (zh) 1998-02-04
NO312814B1 (no) 2002-07-08
JP4516159B2 (ja) 2010-08-04
CZ291349B6 (cs) 2003-02-12
AU695366B2 (en) 1998-08-13
FI973185L (fi) 1997-09-30
LV11940A (lv) 1998-01-20
BG101803A (en) 1998-04-30
SI9620022A (sl) 1998-10-31
NO973531L (no) 1997-09-30
CN1083263C (zh) 2002-04-24
LV11940B (en) 1998-05-20
PL183148B1 (pl) 2002-05-31
WO1996023496A1 (en) 1996-08-08
BG62876B1 (bg) 2000-10-31
DK176081B1 (da) 2006-04-18
FI119586B (fi) 2009-01-15
EE9700166A (et) 1998-02-16
EE03384B1 (et) 2001-04-16
MD1716B2 (en) 2001-08-31
IS1980B (is) 2005-01-14
MX9705856A (es) 1998-07-31
IS4532A (is) 1997-07-25
MD970254A (en) 1999-05-31
NZ298878A (en) 1999-05-28
JPH10513177A (ja) 1998-12-15
CZ240597A3 (cs) 1998-01-14
AT408188B (de) 2001-09-25
ATA901396A (de) 2001-02-15
FI973185A0 (fi) 1997-07-31
SK284521B6 (sk) 2005-05-05
MD1716C2 (ro) 2002-02-28
PL321630A1 (en) 1997-12-08
SK103097A3 (en) 1998-01-14

Similar Documents

Publication Publication Date Title
BR9510510A (pt) Formulação em aerossol farmacêutica uso da mesma e processos para fabricação da mesma para tratamento de um paciente carente de terapia
BR9610248A (pt) Composto composição farmacêutica processos para o tratamento da dor e para a preparação de um composto e uso do composto
PT1037667E (pt) Formulacoes farmaceuticas em hidrogel dispositivos e metodos para administracao de farmacos
FI964028L (fi) Uusi farmaseuttinen formulaatio ja menetelmä
BR9510422A (pt) Formulação em pó para administração de polipeptídeos medicamente úteis uso do pó e processos para fabricação da formulação e para tratamento de um paciente carente de terapia
DE69525148D1 (de) Pharmazeutische formulierung
BR9703624A (pt) Combinação formulação farmacêutica processo para o tratamento de depressão em um animal uso de mirtazapina uso de um ou mais srri's e embalagem
BR9602915A (pt) Medicamentos uso e formulação farmacêutica
CY2007001I2 (el) Φαρμακευτικο σκευασμα για χρηση στη θεραπεια του διαβητη
BR9006924A (pt) Formulacao para tratamento de sintomas e doencas,uso de formulacao para o tratamento de sintomas e doencas,metodo para o tratamento de sintomas e doencas,distribuicao de agentes medicinais e terapeuticos para o tratamento de sintomas e doencas e combinacao para administracao em mamiferos
DE69618587D1 (de) Chinazoline und pharmazeutische zusammensetzungen
BR9510501A (pt) Formulação em aerossol uso da mesma e processos para fabricação da mesma e para tratamento de um paciente carente de terapia
FI953479A0 (fi) 1-aryylipyrimidiinijohdannaiset ja niiden farmaseuttinen käyttö
BR9709267A (pt) Preparação de anticorpo monoclonal para administração a um humano formulação farmacêutica uso de uma preparação de anticorpo monoclonal e processo para a fabricação de uma preparação de anticorpo monoclonal
EE9900075A (et) 7a-( -aminoalküül)östratrieenid, nende valmistamise meetod, 7a-( -aminoalküül)östratrieene sisaldavad farmatseutilised preparaadid ja nende kasutamine ravimite valmistamiseks
ATE221374T1 (de) Lyophilisierte stabile pharmazeutische formulierung
DE69600065D1 (de) Dermatologische und/oder pharmazeutische Zubereitung, ihre Herstellung und Anwendung
BR9510302A (pt) Forma de dosagem farmacêutical de liberação controlada método para tratamento sintomático da tosse método para preparar uma forma de dosagem farmacêutica de liberação controlada composição para uso no tratamento sintomático da tosse e aplicação de uma forma dosagem de moguisteina de liberação controlada
NO961136D0 (no) Farmasöytisk formuleringsgrunnlag for nano-suspensjoner
FI945198L (fi) Farmaseuttiset ja muut annosmuodot
PT1183029E (pt) Preparado farmaceutico contendo contendo o principio activo diamorfina e sua utilizacao num processo para o tratamento da dependencia de opiaceos
BR9607851B1 (pt) combinaÇço e formulaÇço farmacÊutica.
ATE288419T1 (de) Alpha-aryl-n-alkylnitrone sowie diese enthaltende pharmazeutische zubereitungen
EE9600172A (et) Puriin-6-ooni derivaadid, nende valmistamismeetod, kasutamine ravimite valmistamiseks ja ravimid
FI971188L (fi) Terapeuttinen vitamiini-kalsium yhdistelmä yksikköannoksena galeenisen tabletin muodossa, menetelmä sen valmistamiseksi ja sen käyttö

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 37, INDEFIRO O PRESENTE PEDIDO COM BASE NO ART. 229-A DA LEI 10.196 DE 14/02/2001.